We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, Medpace (MEDP - Free Report) closed at $609.89, marking a -1.64% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.02%. On the other hand, the Dow registered a loss of 0.35%, and the technology-centric Nasdaq decreased by 0.15%.
Prior to today's trading, shares of the provider of outsourced clinical development services had gained 4.14% outpaced the Medical sector's gain of 1.06% and the S&P 500's gain of 2.05%.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is slated to reveal its earnings on October 21, 2026. The company is expected to report EPS of $4.45, up 15.28% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $708.75 million, indicating a 7.4% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.54 per share and a revenue of $2.84 billion, indicating changes of +14.79% and +12.38%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Medpace currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Medpace is presently being traded at a Forward P/E ratio of 35.35. This denotes a premium relative to the industry average Forward P/E of 17.86.
It's also important to note that MEDP currently trades at a PEG ratio of 2.77. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.67.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 101, placing it within the top 42% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MEDP in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Medpace (MEDP) Dips More Than Broader Market: What You Should Know
In the latest trading session, Medpace (MEDP - Free Report) closed at $609.89, marking a -1.64% move from the previous day. The stock's performance was behind the S&P 500's daily loss of 0.02%. On the other hand, the Dow registered a loss of 0.35%, and the technology-centric Nasdaq decreased by 0.15%.
Prior to today's trading, shares of the provider of outsourced clinical development services had gained 4.14% outpaced the Medical sector's gain of 1.06% and the S&P 500's gain of 2.05%.
The investment community will be paying close attention to the earnings performance of Medpace in its upcoming release. The company is slated to reveal its earnings on October 21, 2026. The company is expected to report EPS of $4.45, up 15.28% from the prior-year quarter. Alongside, our most recent consensus estimate is anticipating revenue of $708.75 million, indicating a 7.4% upward movement from the same quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $17.54 per share and a revenue of $2.84 billion, indicating changes of +14.79% and +12.38%, respectively, from the former year.
Investors should also note any recent changes to analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Medpace currently has a Zacks Rank of #3 (Hold).
In terms of valuation, Medpace is presently being traded at a Forward P/E ratio of 35.35. This denotes a premium relative to the industry average Forward P/E of 17.86.
It's also important to note that MEDP currently trades at a PEG ratio of 2.77. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.67.
The Medical Services industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 101, placing it within the top 42% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MEDP in the coming trading sessions, be sure to utilize Zacks.com.